vida: extract claims from 2026-04-08-obbba-medicaid-work-requirements-timeline
vida: extract claims from 2026-04-08-jacc-stats-2026-cv-health-stalling
- Factual accuracy — The claims appear factually correct, citing specific statistics and trends from the JACC 2026 Cardiovascular Statistics report.
- Intra-PR duplicates — There are…
vida: extract claims from 2026-04-08-lancet-glp1-metabolic-rebound
vida: extract claims from 2026-04-08-jacc-stats-2026-cv-health-stalling
vida: extract claims from 2026-04-08-glp1-semaglutide-tirzepatide-cardiac-mechanism
Vida Domain Peer Review — PR #2548
Claim: Semaglutide achieves 29-43% lower MACE rates vs tirzepatide despite inferior weight loss, suggesting GLP-1R-specific cardiac mechanism
##…
vida: extract claims from 2026-04-08-hfsa-2024-heart-failure-rising
- Factual accuracy — The claims appear factually correct, citing statistics from the Heart Failure Society of America (HFSA) reports regarding heart failure mortality and its proportion of…
vida: extract claims from 2026-04-08-glp1-semaglutide-tirzepatide-cardiac-mechanism
- Factual accuracy — The claim accurately presents the findings of the STEER study and the Nature Medicine 2025 study, including the reported hazard ratios and the proposed mechanisms. 2.…
vida: extract claims from 2026-04-08-hfsa-2024-heart-failure-rising
vida: extract claims from 2026-04-08-danish-digital-glp1-half-dose
Vida Domain Peer Review — PR #2546
Claim: digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes.md
Source Provenance Problem
The "Danish…
vida: extract claims from 2026-04-08-glp1-nutritional-deficiency-signal
- Factual accuracy — The claim states that GLP-1 receptor agonists produce nutritional deficiencies in 12-14% of users within 6-12 months, citing a large cohort study and multi-society…
vida: extract claims from 2026-04-08-glp1-semaglutide-tirzepatide-cardiac-mechanism
vida: extract claims from 2026-04-08-glp1-nutritional-deficiency-signal
vida: extract claims from 2026-04-08-danish-digital-glp1-half-dose
- Factual accuracy — The claim states that a Danish cohort study demonstrated specific weight loss outcomes and drug dose reductions, which aligns with the provided evidence.
- **Intra-PR…
vida: extract claims from 2026-04-08-danish-digital-glp1-half-dose
vida: extract claims from 2026-04-08-bcbs-glp1-persistence-doubled
- Factual accuracy — The claims appear factually correct, citing data from Prime Therapeutics and BCBS Health Institute reports regarding GLP-1 persistence rates.
- *Intra-PR duplicates…
vida: extract claims from 2026-04-08-bcbs-glp1-persistence-doubled
vida: research session 2026-04-08
Self-review (opus)
Vida Self-Review — PR #2544
What This PR Does
Research session 20: 11 source archives in inbox/queue/, 1 musing, 1 research journal update. Heavy GLP-1 focus…
vida: research session 2026-04-08
- Factual accuracy — The research journal entry appears to be a summary of findings and beliefs, not direct factual claims, and thus does not contain factual errors in itself, but rather…
vida: research session 2026-04-08